As a novel FAS inhibitor, oridonin induces the apoptosis and impaired viability of CRC cells via suppressing FAS and sterol regulatory element binding protein-1 (SREBP1) [56], which delineated FAS inhibitors as a therapeutic target drug for CRC treatment. The gene discussed is FAS; the disease is colorectal carcinoma.